bilaterals.org logo
bilaterals.org logo

medicines


Longer monopolies and single legal proceedings vs. generics - the gift of CETA to Canadian drug patentees
Canadian pharmaceutical patent owners can expect two substantive changes in the next year following implementation of the Canada–European Union trade agreement
Regional trade meet should not pave way for monopoly in drugs: Doctors without Borders
Doctors Without Borders/Medecins Sans Frontieres (MSF) and other health groups have reiterated concerns about harmful intellectual property provisions in the RCEP
TPP may be dead – but its impact lingers
Threats to affordable access to medicines continue unabated
On World AIDS Day, threat to access to medicines looms large
As trade negotiators from 16 countries gather in Indonesia to deliberate the terms of trade agreement — the Regional Comprehensive Economic Partnership agreement (RCEP), access to low-cost generic medicines is under grave threat.
MSF press release: RCEP trade deal negotiators must reject terms that would harm access to medicines
International medical humanitarian organisation Médecins Sans Frontières (MSF), along with other health groups, reiterated concerns about harmful intellectual property provisions in the proposed agreement that would increase market monopolies for pharmaceutical corporations and delay or block access to affordable generic medicines.
Canada-EU trade deal: Costs for new drugs may rise, but not for years
CETA drug-patent extension applies only to new products, and higher costs are likely at least 8 years away
Ottawa didn’t study how much more we’ll pay for drugs under CETA
Experts have been warning for years that Canada’s trade deal with the European Union would add billions to the cost of pharmaceuticals in Canada, but the government itself apparently did not study the issue.
Data exclusivity could go to 12 yrs
US reports that data exclusivity for biologics in Australia could still be extended to 12 years via the TPP trade deal have got local activists up in arms.
Call for Govt to help our neighbours negotiate for life-saving medicines
The Public Health Association (PHA) is asking the NZ government to step in and help our neighbouring countries negotiate better deals for life-saving medicines.
India to US: Will not tighten IPR rules beyond TRIPS mandate
India and the US continued to differ on the issue of intellectual property rights (IPR) norms in their bilateral trade and investment policy discussions
Activists fret about RCEP impact
Access to affordable medicine and farmers’ control over seeds could be undermined by the Regional Comprehensive Economic Partnership being negotiated between Asean member countries and six other trade partners, says FTA Watch in Thailand
An open letter to the sixteen governments negotiating the Regional Comprehensive Economic Partnership (RCEP)
95 health, community and development organisations in the Asia Pacific region call on trade negotiators from sixteen countries in the Regional Comprehensive Economic Partnership agreement negotiations to ensure access to medicines is protected. We the undersigned organisations call on negotiators to protect health and reject all TRIPS plus intellectual property measures in the RCEP.
Open letter to ambassadors (in India) of RCEP negotiating countries by Delhi Network of Positive People
Member countries must consider the impact of RCEP on access to medicines in developing countries
The Aids revolution is why Asean, India and China must resist controls on generic drugs
Affordable generics have transformed medical treatment, yet intellectual property provisions in a China-led regional trade deal could block access to life-saving drugs for millions in Africa and Asia
In boon for Big Pharma, TTIP would lock in high drug prices: report
’Unfortunately, trade agreements have become one more mechanism for drug corporations to expand their monopoly power’
Big Pharma lobbying in TTIP: Bad news for patients
Big Pharma is everything but shy when it comes to lobbying EU policy-makers. But what exactly are these groups lobbying for in TTIP?
US pressures Australia for stronger TPP biologics monopolies
According to the Bloomberg, Senator Hatch said “They’re going to have to find a way of having the countries agree to change that formality in the TPP to 12 years…If Australia wants to be part of it, they have to meet our terms,”
Call to remove IP clauses from trade pact
As the next round of Regional Comprehensive Economic Partnership (RCEP) trade talks begin in Vietnam, humanitarian aid organisation Médecins Sans Frontières calls for the removal of intellectual property provisions from the agreement
Clause for evergreening of patents dropped from RCEP: Nirmala
Provisions related to evergreening of patents in the proposed Regional Comprehensive Economic Partnership Agreement (RCEP) was dropped after stiff opposition from India, Parliament was informed today.
TPP heightens urgency for national drug coverage in Canada
Adopting a national pharmacare program would offset the higher drug prices expected with the ratification of the Trans-Pacific Partnership, write Tanishq Suryavanshi and Jake Hirsch-Allen.